CG
CARM

Cutler Group’s Carisma Therapeutics CARM Stock Holding History

Cutler Group’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,790
Closed -$3K – 5357
2021
Q4 		$3K Sell
2,790
-1,985
-42% -$40K ﹤0.01% 4471
2021
Q3 		$6K Buy
4,775
+1,035
+28% +$49.7K ﹤0.01% 4303
2021
Q2 		$88K Buy
3,740
+2,625
+235% +$167K ﹤0.01% 1991
2021
Q1 		$25K Buy
+1,115
New +$52.6K ﹤0.01% 3013
2020
Q4 		– Sell
-1,000
Closed -$11K – 4840
2020
Q3 		$11K Buy
+1,000
New +$20K ﹤0.01% 2895
2016
Q4 		– Sell
-495
Closed -$1K – 6547
2016
Q3 		$1K Buy
+495
New +$36.9K ﹤0.01% 6038

Other funds holding CARM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
TOTUOP
Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $297M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Cutler Group's CARM Position: Q1 2024 in Review

Cutler Group sold out of Carisma Therapeutics (CARM) in Q1 2024, closing a stake of 5 shares.

Cutler Group first reported a position in CARM in Q2 2016 and held it in 26 quarters. The position peaked at $211K in Q2 2021. 51 funds tracked by Wall St. Rank hold CARM as of Q1 2024.

  • Cutler Group reported no remaining Carisma Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 5 Carisma Therapeutics shares in Q1 2024.
  • Cutler Group first reported a position in Carisma Therapeutics in Q2 2016 and held it in 26 quarters.
  • Cutler Group's Carisma Therapeutics position peaked at $211K in Q2 2021.
  • 51 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.